GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Viemed Healthcare Inc (NAS:VMD) » Definitions » Sloan Ratio %

Viemed Healthcare (Viemed Healthcare) Sloan Ratio % : 18.09% (As of Mar. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Viemed Healthcare Sloan Ratio %?

Richard Sloan from the University of Michigan was first to document what is referred to as the "accrual anomaly". His 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones.

Viemed Healthcare's Sloan Ratio for the quarter that ended in Mar. 2024 was 18.09%.

As of Mar. 2024, Viemed Healthcare has a Sloan Ratio of 18.09%, indicating there is a warning stage of accrual build up.


Viemed Healthcare Sloan Ratio % Historical Data

The historical data trend for Viemed Healthcare's Sloan Ratio % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Viemed Healthcare Sloan Ratio % Chart

Viemed Healthcare Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Sloan Ratio %
Get a 7-Day Free Trial 2.72 4.30 5.41 2.09 11.07

Viemed Healthcare Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Sloan Ratio % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.84 15.53 14.45 11.07 18.09

Competitive Comparison of Viemed Healthcare's Sloan Ratio %

For the Medical Devices subindustry, Viemed Healthcare's Sloan Ratio %, along with its competitors' market caps and Sloan Ratio % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Viemed Healthcare's Sloan Ratio % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Viemed Healthcare's Sloan Ratio % distribution charts can be found below:

* The bar in red indicates where Viemed Healthcare's Sloan Ratio % falls into.



Viemed Healthcare Sloan Ratio % Calculation

Earnings contain a lot of non cash earnings which is called accruals. The Sloan ratio is a way to identify firms with low non-cash or accrual-derived earnings relative to their cash flow.

Viemed Healthcare's Sloan Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Sloan Ratio=(Net Income (A: Dec. 2023 )-Cash Flow from Operations (A: Dec. 2023 )
-Cash Flow from Investing (A: Dec. 2023 ))/Total Assets (A: Dec. 2023 )
=(10.243-45.212
--52.113)/154.895
=11.07%

Viemed Healthcare's Sloan Ratio for the quarter that ended in Mar. 2024 is calculated as

Sloan Ratio=(Net Income (TTM)-Cash Flow from Operations (TTM))
-Cash Flow from Investing (TTM))/Total Assets (Q: Mar. 2024 )
=(10.329-35.891
--53.573)/154.875
=18.09%

Viemed Healthcare's Net Income for the trailing twelve months (TTM) ended in Mar. 2024 was 2.33 (Jun. 2023 ) + 2.919 (Sep. 2023 ) + 3.477 (Dec. 2023 ) + 1.603 (Mar. 2024 ) = $10.3 Mil.
Viemed Healthcare's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2024 was 7.623 (Jun. 2023 ) + 13.809 (Sep. 2023 ) + 13.284 (Dec. 2023 ) + 1.175 (Mar. 2024 ) = $35.9 Mil.
Viemed Healthcare's Cash Flow from Investing for the trailing twelve months (TTM) ended in Mar. 2024 was -32.207 (Jun. 2023 ) + -8.508 (Sep. 2023 ) + -7.493 (Dec. 2023 ) + -5.365 (Mar. 2024 ) = $-53.6 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Viemed Healthcare  (NAS:VMD) Sloan Ratio % Explanation

A former University of Michigan researcher, Richard Sloan's 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones. In fact, for the 40-year period between 1962 and 2001, buying the lowest accrual companies and shorting the highest accrual companies resulted in an average annual compounded return of 18%, more than double the S&P 500's 7.4% annual return over the same period.

According to How to Beat the Market with the Sloan Ratio:

If the Sloan Ratio is between -10% and 10%, the company is in the safe zone and there is no funny business with accruals.

If the Sloan Ratio is less than between -25% and -10% on the negative side, and between 10% and 25% on the positive side, this is a warning stage of accrual build up.

If the Sloan Ratio is less than -25% or greater than 25%, and this ratio is consistent over several quarters or even years, be careful. Earnings are highly likely to be made up of accruals.

As of Mar. 2024, Viemed Healthcare has a Sloan Ratio of 18.09%, indicating there is a warning stage of accrual build up.


Viemed Healthcare Sloan Ratio % Related Terms

Thank you for viewing the detailed overview of Viemed Healthcare's Sloan Ratio % provided by GuruFocus.com. Please click on the following links to see related term pages.


Viemed Healthcare (Viemed Healthcare) Business Description

Traded in Other Exchanges
Address
625 E. Kaliste Saloom Road, Lafayette, LA, USA, 70508
Viemed Healthcare Inc is a provider of equipment and home therapy to patients with respiratory disease, oxygen problems, sleep apnea and PAP treatment. The company also provides services such as respiratory disease management, neuromuscular care, in-home sleep testing and sleep apnea treatment, oxygen therapy, respiratory equipment rentals, and healthcare staffing services.
Executives
Jeremy Trahan officer: Chief Legal Officer 625 E. KALISTE SALOOM RD., LAFAYETTE LA 70508
Timothy Smokoff director 625 E KALISTE SALOOM RD, LAFAYETTE LA 70508
Nitin Kaushal director 625 E KALISTE SALOOM RD, LAFAYETTE LA 70508
Randy E. Dobbs director C/O VIEMED HEALTHCARE, INC, 625 E. KALISTE SALOOM RD, LAFAYETTE LA 70508
Bruce D Greenstein director 901 HUGH WALLIS ROAD SOUTH, LAFAYETTE LA 70508
William Todd Zehnder director, officer: Chief Operating Officer 400 E. KALISTE SALOOM ROAD, SUITE 6000, LAFAYETTE LA 70508
Casey Hoyt director, officer: Chief Executive Officer 625 E. KALISTE SALOOM RD., LAFAYETTE LA 70508
Michael Moore officer: President 625 E. KALISTE SALOOM RD., LAFAYETTE LA 70508
Trae Fitzgerald officer: Chief Financial Officer 625 E KALISTE SALOOM RD, LAFAYETTE LA 70508
William Frazier director, officer: Chief Medical Officer 625 E KALISTE SALOOM RD, LAFAYETTE LA 70508
Jerome Cambre officer: Vice President of Sales 625 E KALISTE SALOOM RD, LAFAYETTE LA 70508
Sabrina Heltz director 625 E. KALISTE SALOOM ROAD, LAFAYETTE LA 70508
Ewell Patrick Eagan officer: General Counsel 625 E. KALISTE SALOOM ROAD, LAFAYETTE LA 70508